clinical trial · NCT05720117
A Study of PYX-201 in Advanced Solid Tumors
Solid TumorAdvanced Solid TumorPYX-201
brief summary
The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.
started
Mar 14, 2023
primary completion
Jul 1, 2026
completion
May 1, 2027
last updated
Mar 20, 2026
official title
A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol